ASTRO 2017: Long-Term Data Support Single SBRT Dose in Certain Early Lung Cancers
This video reviews long-term results of the NRG Oncology RTOG 0915 trial, a randomized phase II study that compared stereotactic body radiation therapy delivered in one fraction vs four fractions for stage I peripheral non–small-cell lung cancer patients with unresectable disease.
In this video, Gregory M. M. Videtic, MD, CM, of the Cleveland Clinic in Ohio, discusses long-term results of the NRG Oncology RTOG 0915 trial, a randomized phase II study that compared one fraction (34 Gy) of stereotactic body radiation therapy (SBRT) vs 48 Gy in four fractions for stage I peripheral non–small-cell lung cancer patients with unresectable disease.
Videtic presented results of the study (abstract 33) at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held September 24–27 in San Diego.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
